Antiepileptic Medications Safe in Multiple Myeloma
Levetiracetam is the preferred antiepileptic drug for patients with multiple myeloma, as it avoids enzyme-inducing effects that can compromise chemotherapy efficacy and does not require dose adjustment in most cases. 1, 2
Why Avoid Enzyme-Inducing Antiepileptics
Enzyme-inducing antiepileptic drugs (EIAEDs) such as phenytoin, carbamazepine, and phenobarbital are contraindicated in multiple myeloma patients receiving chemotherapy. These agents induce cytochrome P450 enzymes and significantly reduce plasma concentrations and therapeutic effects of multiple myeloma treatments including:
- Proteasome inhibitors (bortezomib, carfilzomib)
- Immunomodulatory drugs (lenalidomide, pomalidomide, thalidomide)
- Alkylating agents (cyclophosphamide, melphalan)
- Corticosteroids (dexamethasone)
- Taxanes and vinca alkaloids if used in combination regimens 2, 3, 4
This enzyme induction persists throughout treatment duration and can lead to treatment failure, disease progression, and increased mortality 4. The interactions are bidirectional—cisplatin and corticosteroids can also reduce phenytoin effectiveness, creating a vicious cycle of poor seizure control 2, 3.
Recommended Antiepileptic Drugs
First-Line Choice: Levetiracetam
- No enzyme induction or inhibition
- No dose adjustment needed in most myeloma patients
- Well-tolerated with favorable side effect profile compared to older agents 1, 5
- Does not interfere with chemotherapy metabolism
- Effective for seizure prevention in brain metastases (7-day postoperative period) 1
Alternative Non-Enzyme-Inducing Options:
- Gabapentin
- Lamotrigine (caution: oral contraceptives increase its metabolism, though less relevant in myeloma population)
- Pregabalin
- Topiramate
- Zonisamide 3, 5
Valproic Acid: Use With Extreme Caution
While valproic acid is non-enzyme-inducing, it carries significant risks in multiple myeloma:
- Grade 3-4 hematologic toxicity when combined with temozolomide or other chemotherapy 1
- Thrombocytopenia and hepatotoxicity 1
- Can inhibit metabolism of etoposide and nitrosoureas, leading to chemotherapy toxicity 2, 3
- Methotrexate reduces valproic acid effectiveness 2
Valproic acid should only be considered if levetiracetam and other alternatives fail or are contraindicated, and requires close hematologic monitoring 1.
Clinical Algorithm
For seizure prophylaxis or treatment in multiple myeloma patients:
- Start levetiracetam as first-line agent
- If levetiracetam fails or causes intolerable side effects → switch to gabapentin, pregabalin, or lamotrigine
- If all non-enzyme-inducing alternatives fail → consider valproic acid with intensive monitoring (CBC every 2-3 days initially, then weekly)
- Never use phenytoin, carbamazepine, phenobarbital, or primidone in patients receiving active myeloma therapy
Critical Pitfalls to Avoid
- Do not assume older antiepileptics are acceptable because they're familiar—enzyme induction compromises cancer treatment 4
- Switching from enzyme-inducing to non-inducing agents requires careful monitoring: withdrawal of EIAEDs will increase chemotherapy drug concentrations, potentially causing toxicity if doses aren't adjusted 4
- If patient is already on an EIAED, switch to levetiracetam immediately and consider whether chemotherapy doses need adjustment
- Prophylactic antiepileptics are not routinely recommended for brain metastases without prior seizures, but if used, levetiracetam is the agent of choice 1
Special Considerations in Multiple Myeloma
Given that myeloma patients often have:
- Renal impairment: Levetiracetam requires dose adjustment only if CrCl <30 mL/min 5
- Thrombocytopenia: Avoid valproic acid which worsens platelet counts 1
- Polypharmacy: Non-enzyme-inducing agents minimize drug-drug interactions 6, 4
- Immunosuppression: Enzyme-inducing AEDs also reduce levels of antibiotics, antivirals, and immunosuppressants 6, 4